Litigation Details for AMGEN INC v. SANDOZ INC. (D.N.J. 2018)
✉ Email this page to a colleague
AMGEN INC v. SANDOZ INC. (D.N.J. 2018)
| Docket | ⤷ Start Trial | Date Filed | 2018-06-26 |
| Court | District Court, D. New Jersey | Date Terminated | 2021-09-28 |
| Cause | 15:1126 Patent Infringement | Assigned To | Michael Andre Shipp |
| Jury Demand | None | Referred To | Douglas Arpert |
| Parties | CELGENE CORPORATION; SANDOZ INC. | ||
| Patents | 10,092,541; 6,962,940; 7,208,516; 7,427,638; 7,659,302; 7,893,101; 8,455,536; 8,802,717; 9,018,243; 9,724,330; 9,872,854 | ||
| Attorneys | AUROBINDO PHARMA LIMITED; STEPHEN M. KLEIN | ||
| Firms | Benesch Friedlander Coplan & Aronoff LLP; Yevgenia Shtilman Kleiner | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AMGEN INC v. SANDOZ INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .
Details for AMGEN INC v. SANDOZ INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-06-26 | External link to document | |||
| 2018-06-26 | 1 | Complaint | United States Patent Nos. 6,962,940 (“the ’940 Patent”), 7,208,516 (“the ’516 Patent”), 7,427,638 (“… U.S. Patent Nov. 8, 2005 Sheet 1 of 2 US 6,962,940 B2 …PageID: 71 U.S. Patent Nov. 8, 2005 Sheet 2 of 2 US 6,962,940 B2 … US 6,962,940 B2 Muller et al. (45) Date… US 6,962,940 B2 | External link to document |
| 2018-06-26 | 355 | In Limine | Infringement Opinions of Dr. Alexis Regarding U.S. Patent No. 10,092,541 by ALKEM LABORATORIES LTD.. (CAPUZZI, KEVIN… 28 September 2021 3:18-cv-11026 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
